1.
Makheja AN, Bailey JM. A platelet phospholipase
inhibitor from the medicinal herb feverfew (Tanacetum
parthenium). Prostagland Leukotrienes Med
1982;8:653–60.
2.
Heptinstall S, White A, Williamson L, Mitchell
JR.. Extracts of feverfew inhibit granule secretion
in blood platelets and polymorphonuclear leukocytes.
Lancet 1985;1:1071–4.
3.
Awang DVC. Parthenolide: The demise of a facile
theory of feverfew activity. J Herbs Spices
Medicinal Plants 1998;5:95–8.
4.
Johnson ES, Kadam NP, Hylands DM, Hylands PJ.
Efficacy of feverfew as prophylactic treatment
of migraine. Br Med J 1985;291:569–73.
5.
Murphy JJ, Heptinstall S, Mitchell JRA. Randomised
double-blind placebo-controlled trial of feverfew
in migraine prevention. Lancet 1988;2:189–92.
6.
Palevitch D, Earon G, Carasso R. Feverfew(Tanacetum
parthenium) as a prophylactic treatment for
migraine: A double-blind placebo-controlled study.
Phytother Res 1997;11:508–11.
7.
De Weerdt CJ, Bootsma HPR, Hendriks H. Herbal
medicines in migraine prevention. Phytomed
1996;3:225–30.
8.
Wagner H, Horhammer L, Munster R. The chemistry
of silymarin (silybin), the active principle of
the fruits of Silybum marianum (L.) Gaertn.
Arzneim-Forsch Drug Res 1968;18:688–96.
9.
Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic
actions of flavonolignans from Silybum marianum
fruits. Planta Medica 1984;50:248–50.
10.
Faulstich H, Jahn W, Wieland T. Silibinin inhibition
of amatoxin uptake in the perfused rat liver.
Arzneim-Forsch Drug Res 1980;30:452–4.
11.
Tuchweber B, Sieck R, Trost W. Prevention by silibinin
of phalloidin induced hepatotoxicity. Toxicol
Appl Pharmacol 1979;51:265–75.
12.
Feher J, Lang I, Deak G, et al. Free radicals
in tissue damage in liver diseases and therapeutic
approach. Tokai J Exp Clin Med 1986;11:121–34.
13.
Sonnenbichler J, Zetl I. Stimulating influence
of a flavonolignan derivative on proliferation,
RNA synthesis and protein synthesis in liver cells.
In Assessment and Management of Hepatobiliary
Disease, ed. L Okolicsanyi, G Csomos, G Crepaldi.
Berlin: Springer-Verlag, 1987, 265–72.
14.
Salmi HA, Sama S. Effect of silymarin on chemical,
functional and morphological alterations of the
liver. Scand J Gastroenterol 1982;17:517–21.
15.
Ferenci P, Dragosics B, Dittrich H, et al. Randomized
controlled trial of silymarin treatment in patients
with cirrhosis of the liver. J Hepatol
1989;9:105–13.
16.
Velussi M, Cernogoi AM, De Monte A, et al. Long-term
(12 months) treatment with an antioxidant drug
(silymarin) is effective on hyperinsulinemia,
exogenous insulin need and malondialdehyde levels
in cirrhotic diabetic patients. J Hepatology
1997;26:871–9.
17.
Pares A, Plancs R, Torres M, et al. Effects of
silymarin in alcoholic patients with cirrhosis
of the liver: results of a controlled, double-blind,
randomized and multicenter trial. J Hepatol
1998;28:615–21.
18.
Nassuato G, Iemmolo RM, Strazzabosco M, et al.
Effect of silibinin on biliary lipid composition.
Experimental and clinical study. J Hepatol
1991;12:290–5.
19.
Palasciano G, Portinascasa P, Palmieri V, et al.
The effect of silymarin on plasma levels of malondialdehyde
in patients receiving long-term treatment with
psychotropic drugs. Curr Ther Res 1994;S5:S37–45.
20.
Allain H, Schück S, Lebreton S, et al. Aminotransferase
levels and silymarin in de novo tacrine-treated
patients with Alzheimer’s disease. Dementia
Geriatr Cogn Disorders 1999;10:181–5.